The study will investigate whether PD-L1 and other immuno-markers will be influenced by osimertinib treatment in advanced epidermal growth factor receptor (EGFR)T790M positive advanced NSCLC patients. In addition, we will explore whether PD-L1 and other immuno-markers can predict the safety and efficacy of subsequent use of immune checkpoint inhibitors at the time of PD due to osimertinib resistance.
Name: No interventions will be taken in this Observational study
Description: Measure PD-L1 value Change by tumor cells(TC)/immune cells(IC) staining from the baseline to progressive disease(PD)
Measure: Measure PD-L1 value Time: baseline and PD,up to 24 monthsDescription: Measure PD-L1 expression positive rate (%) change from the baseline to progressive disease(PD)
Measure: Measure PD-L1 expression positive rate (%) Time: baseline and PD,up to 24 monthsCase-Only
There is one SNP
Small Cell Lung Cancer, Polygonal Type Lung Neoplasms Small Cell Lung Carcinoma Investigate whether PD-L1 and other immuno-markers will be influenced by osimertinib treatment in advanced EGFR T790M positive advanced NSCLC patients. --- T790M ---